--- title: 'Life Sciences Daily Summary: What Happened on October 6, 2026' headline: Survodutide cuts weight by up to 13.1% in Phase 3 obesity trial description: Lymphoma results and three deals added clinical and business news. url: https://thebench.bio/news/summaries/2026-10-06 topic: all date: '2026-10-06' covers: - '2026-10-06' date_published: '2026-10-06T18:52:47Z' date_modified: '2026-10-06T18:52:47Z' sources: 10 publisher: The Bench (thebench.bio) --- # Life Sciences Daily Summary: What Happened on October 6, 2026 **Survodutide cuts weight by up to 13.1% in Phase 3 obesity trial** Lymphoma results and three deals added clinical and business news. ## Today in brief Boehringer Ingelheim’s survodutide met both primary endpoints in a Phase 3 trial of adults with obesity or overweight and type 2 diabetes, with weight loss reaching 13.1% over 76 weeks. [1] [2] Genmab and AbbVie said epcoritamab plus R-CHOP lowered the likelihood of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma. [3] [4] Roche licensed Alector’s preclinical Parkinson’s candidate AL050 for $100 million upfront and up to $1.17 billion in milestones. [5] CSL agreed to pay Alentis $355 million upfront for a lixudebart collaboration, while Shionogi plans to buy IntraBio for $2 billion and gain rights to Aqneursa. [6] [7] [8] ## Survodutide met both Phase 3 endpoints, but gastrointestinal effects led some patients to stop The 755-person SYNCHRONIZE-2 trial met both co-primary endpoints: weight change and the share of participants who lost at least 5% of their weight. [2] At week 76, average weight loss reached 13.1% with survodutide versus 3.1% with placebo under an analysis that assumes participants stayed on treatment. [1] [2] When the analysis included outcomes regardless of whether participants stopped treatment, weight loss was 9.8% at the 6.0-mg dose and 8.2% at 3.6 mg, versus 3.9% with placebo. [2] The drug also reduced HbA1c, a measure of average blood sugar, by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 points on placebo. [1] [2] Gastrointestinal events led 18% of survodutide recipients to stop treatment, compared with 1.2% of placebo recipients, usually during dose escalation. [2] Boehringer Ingelheim said a rigid dose-escalation schedule may have contributed to the discontinuations. The company said newer trials allow more flexible dose increases. [2] Survodutide is an investigational dual glucagon and GLP-1 receptor agonist and is not approved in any market. [1] [2] The trial compared it with placebo, not approved incretin medicines, so its performance against those treatments remains unknown. [2] ## Epcoritamab plus R-CHOP lowered progression-or-death risk by 51% in lymphoma An interim analysis of the Phase 3 EPCORE DLBCL-2 trial found that epcoritamab plus R-CHOP significantly improved progression-free survival compared with R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. [4] The combination reduced the likelihood of disease progression or death by 51%, and its reported safety profile was generally consistent with what was already known about the medicines. [3] [4] An independent data monitoring committee recommended unblinding the study after the benefit emerged. [4] The companies plan to present the full results at a future medical meeting and discuss next steps with regulators. [4] The combination remains investigational in this setting. The trial compared it with R-CHOP alone, not the Polivy-based regimen used in frontline care. [3] [4] ## Roche pays Alector $100 million upfront for a preclinical Parkinson’s candidate Roche licensed global rights to AL050, a preclinical enzyme replacement therapy designed to address GCase deficiency in Parkinson’s disease. [5] Alector is eligible for up to $1.17 billion in development, regulatory and commercial milestones, bringing the deal’s potential value to $1.27 billion. [5] Genentech will lead development, regulatory work, manufacturing and commercialization across indications. [5] Alector retains ownership of its ABC delivery platform, which the company says is designed to carry therapies across the blood-brain barrier. [5] ## CSL commits $355 million upfront to Alentis’s kidney and liver drug CSL signed an exclusive collaboration with Alentis Therapeutics to develop and commercialize lixudebart for kidney and liver diseases. [6] Alentis will receive $355 million upfront and may collect up to $1.2 billion in commercial milestones. [6] The agreement covers the ongoing Phase II RENAL study in ANCA-associated vasculitis with rapidly progressive glomerulonephritis, as well as development in focal segmental glomerulosclerosis and primary sclerosing cholangitis. [6] [9] Alentis reported that an interim analysis of 26 RENAL patients found improvements in kidney function and proteinuria after 24 weeks. [10] The company also reported improved liver function after six weeks in a Phase Ib study of lixudebart in advanced liver fibrosis. [10] ## Shionogi plans $2 billion purchase of IntraBio and its rare-disease drug Shionogi announced on October 5 that it would acquire IntraBio for $2 billion, gaining global rights to Aqneursa if the deal closes. [7] [8] Aqneursa is approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C. The FDA expanded its US use to ataxia-telangiectasia, and European regulators are reviewing the drug for that condition. [7] [8] Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue and that it expects the acquisition to close by year-end, subject to regulatory review. [8] The purchase would add to Shionogi’s rare-disease portfolio after its acquisition of global rights to the amyotrophic lateral sclerosis drug Radicava earlier in 2026. [7] [8] ## The day in numbers - **13.1%**: Maximum average weight loss with survodutide at 76 weeks under the analysis assuming participants stayed on treatment. [1] [2] - **51%**: Reduction in progression-or-death risk with epcoritamab plus R-CHOP in the interim lymphoma analysis. [3] [4] - **$1.27 billion**: Potential total value of Roche’s license deal for Alector’s AL050, including $100 million upfront. [5] - **$355 million**: Upfront payment CSL agreed to make to Alentis for the lixudebart collaboration. [6] - **$2 billion**: Price Shionogi expects to pay for IntraBio, including Aqneursa. [7] [8] ## Sources 1. [Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial](), Pharmafile, 2026-10-06 2. [Survodutide Meets Co-Primary Weight Loss Endpoints in Phase 3 SYNCHRONIZE-2 Trial in Obesity and Type 2 Diabetes](), BioPharm International, 2026-10-05 3. [Genmab and AbbVie’s bispecific antibody halves progression-or-death risk in lymphoma trial](), European Biotechnology, 2026-10-06 4. [AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial](), Clinical Trials Arena, 2026-10-06 5. [Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal](), Pharmaceutical Technology, 2026-10-06 6. [CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug  ](), Pharmaceutical Technology, 2026-10-06 7. [Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout  ](), Pharmaceutical Technology, 2026-10-06 8. [Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition](), MedCity News, 2026-10-05 9. [Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership](), Pharmaceutical Executive, 2026-10-05 10. [CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal](), European Biotechnology, 2026-10-05 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: